LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer.

Xichun Hu(Fudan University Shanghai Cancer Center), Biyun Wang(Fudan University Shanghai Cancer Center), Fuming Qiu(Second Affiliated Hospital of Zhejiang University), Changlu Hu(Anhui Provincial Hospital), Weimin Xie(Guangxi Medical University), Xinlan Liu(Yunnan Agricultural University), Guie Lai(First Affiliated Hospital of Jiangxi Medical College), Zhongsheng Tong(Institute of Oncology NN Petrov), Wei Li(Jilin University), Shusen Wang(Sun Yat-sen University), Bing Zhao(Xinjiang Medical University), Ying Cheng(Jilin Province Tumor Hospital), Xinshuai Wang(Henan University of Science and Technology), Tao Sun(The Central Hospital of Shaoyang), Tong Li(Hunan University), Lihua Song(Shandong Tumor Hospital), Xi Yan(Sichuan University), Jinke Pang
Journal of Clinical Oncology
June 1, 2024
10.1200/jco.2024.42.16_suppl.1052
Cited by 1

Related Papers

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Induction of Pyroptosis and Its Implications in Cancer Management
|Frontiers in Oncology|2019|274
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
|JAMA|2020|229
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
|Journal of Clinical Oncology|2024|163
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
|Nature Medicine|2024|121